Haemonetics Starts Fiscal 2027 Strong, Raises Outlook as CSL Overhang Fades

What happened

Haemonetics opened fiscal 2027 with first-quarter revenue rising 6% year over year to $339 million and adjusted EPS up 4% to $1.14, prompting a full-year guidance raise. The growth was broad-based, spanning both the MedSurg (Hospital) and apheresis (Plasma) businesses, signaling that the CSL Plasma transition headwind is largely absorbed. Management maintained disciplined assumptions, suggesting potential for further upside if current trends hold. The result validates the company’s portfolio tilt toward higher-growth areas and suggests the trough flagged in the prior master report has passed. Execution in Hospital remains robust, and Plasma stabilization is becoming evident, improving near-term visibility.

Implication

For investors, the Q1 beat and raised outlook signal that the CSL Plasma overhang is digested, restoring top-line growth. Hospital segment strength, driven by electrophysiology and vascular closure, remains a durable growth engine. The raised guidance, while still conservative, provides visibility and could lead to multiple expansion as the market prices in a return to steady growth. However, Plasma recovery must be monitored for durability, and the balance sheet flexibility via buybacks offers downside support. At ~11.7x trailing earnings, the stock still trades at a discount to peers, leaving room for re-rating if execution continues.

Thesis delta

The prior thesis was constrained by CSL Plasma transition uncertainty; Q1 results showing 6% organic growth and a raised outlook provide concrete evidence of stabilization and recovery. The risk-reward shifts from neutral to more constructive, though consistent execution across both segments is needed to confirm a durable turnaround. Multiple re-rating potential improves as the earnings mix continues to tilt toward higher-growth Hospital.